Global disease burden due to antibiotic resistance – state of the evidence

Por Woolhouse, Mark, Waugh, Catriona, Perry, Meghan Rose, Nair, Harish
Publicado no J Glob Health (2016)

Chronic exposure to arsenic in drinking water can lead to resistance to antimonial drugs in a mouse model of visceral leishmaniasis

Por Perry, Meghan R., Wyllie, Susan, Raab, Andrea, Feldmann, Joerg, Fairlamb, Alan H.
Publicado em 2013

Visceral Leishmaniasis and Arsenic: An Ancient Poison Contributing to Antimonial Treatment Failure in the Indian Subcontinent?

Por Perry, Meghan R., Wyllie, Susan, Prajapati, Vijay Kumar, Feldmann, Joerg, Sundar, Shyam, Boelaert, Marleen, Fairlamb, Alan H.
Publicado em 2011

Arsenic Exposure and Outcomes of Antimonial Treatment in Visceral Leishmaniasis Patients in Bihar, India: A Retrospective Cohort Study

Por Perry, Meghan R., Prajapati, Vijay K., Menten, Joris, Raab, Andrea, Feldmann, Joerg, Chakraborti, Dipankar, Sundar, Shyam, Fairlamb, Alan H., Boelaert, Marleen, Picado, Albert
Publicado no PLoS Negl Trop Dis (2015)

The R Enantiomer of the Antitubercular Drug PA-824 as a Potential Oral Treatment for Visceral Leishmaniasis

Por Patterson, Stephen, Wyllie, Susan, Stojanovski, Laste, Perry, Meghan R., Simeons, Frederick R. C., Norval, Suzanne, Osuna-Cabello, Maria, De Rycker, Manu, Read, Kevin D., Fairlamb, Alan H.
Publicado em 2013

A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041)

Por Chiu, Joanne W., Hotte, Sebastien J., Kollmannsberger, Christian K., Renouf, Daniel J., Cescon, David W., Hedley, David, Chow, Sue, Moscow, Jeffrey, Chen, Zhuo, Perry, Meghan, Diaz-Padilla, Ivan, Tan, David, Hirte, Hal, McWhirter, Elaine, Chen, Helen, Siu, Lillian L., Bedard, Philippe L.
Publicado no Invest New Drugs (2015)